证券代码： 000813 证券简称：天山纺织 编号：2014-09-25 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | 参与单位名称及 | | 上海证券报：樊英利、刘宏鹏、郑培源、徐晶晶、周鲁； | | 人员姓名 | | 西南证券：柯靓、於铀强、张煦。 | | 时间 | 2014 年 9 月 25 | 日上午 10： 30-12:30 点 | | 地点 | 公司 3 楼会议室 | | | 上市公司接待人 | | 董事长：武宪章；总经理：王广斌；副总经理：余熊来；副 | | 员姓名 | | 总经理、董秘：魏哲明；证券事务代表：蒋欣 ...

证券代码： 000813 证券简称：天山纺织 编号：2015-04-03 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-06-27 | --- | --- | --- | --- | |--------------------|-----------------------------------|----------------------------------------------|-------| | | | | | | | √ 特定对象调研 □分析师会议 | | | | | □ 媒体采访 □业绩说明会 | | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ 其他 （请文字说明其他活动内容） | | | | | 安信证券：崔文亮、孔令岩、肖寒 | | | | | | 中信证券资管：吴晓雯、于聪 国寿安保：刘志军 | | | | | 囯信证券：江维娜、徐巍 华商基金：张晓 华夏基 | | | 参与单位名称及人员 | 金：杨杨 嘉实基金：高兰君 | | | | | | 九州证券：岳志强 神农投资：殷南秋 | | | 姓名 | | 农银人寿：冯安铭、周建 ...

证券代码： 000813 证券简称：天山纺织 编号：2016-09-08 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | 参与单位名称及 | 西南证券：周平 | | | 人员姓名 | 建信养老基金：蒋锦 | | | | 东兴证券：胡偌碧 | | | | | 信达证券：单丹、张华、钟惠、胡申、李惜浣 | | | 新华汇嘉：戴泽龙 | | | | 中邮基金：陈梁 | | | | 中银基金：梦圆 | | | | 天风证券：廖庆阳 | | | | 建信基金：陈洁馨 | | | | 新华基金：潮礼君 | | | | 东方证券：季序我 | | | | 天弘基金：刘 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-07-18 | --- | --- | --- | |--------------------|-----------------------------------------------|------------------------------------------| | | | | | | √ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | | | 华创证券：张文录、孙 渊 东方基金：欧阳娟 | | 参与单位名称及人员 | | 天安保险：金春萍 征金资本：唐爽爽 | | 姓名 | | 星石投资：何豪杰 玺萌财富：王齐越 | | | | 盛盈资本：袁清慧 渤海汇金证券：张雷 | | 时 间 | 2017 年 7 月 18 日 | 30 分至 17 点 | | 地 点 | 公司会议室 | | | 公司接待人员姓名 | 董 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-11-7 | --- | --- | --- | |--------------------|----------------------------------|---------------------------------------------| | | | | | | √ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 （请文字说明其他活动内容） | | | | | 中欧基金：卢博森 兴业证券：杜向阳 | | 参与单位名称及人员 | | 国投瑞银：谢允昌 国寿安保基金：刘志军、李丹 | | | | 国寿资产：丁天宇、赵文龙 华榛投资：杨清 | | 姓名 | | 泓德基金：操昭煦 工银瑞信：卢静 | | | | 信诚基金：郑伟 鹏华基金：葛谨洁 | | 时 间 | 2017 年 11 月 7 日 | 点 30 分至 17 点 15 分 | | 地 点 | 公 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2018-6-27 | --- | --- | --- | |--------------------|-----------------------------------------|-----------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 东方证券：刘恩阳 孙瞳 邓振 王凯乐 苗喆 王丽颖 | | 参与单位名称及人员 | | 浙银合一：王聪 霍伟 方正证券：卫马清 | | 姓名 | | 国泰基金：姜英 金满汇投资：李太辉 | | | | 玖麟投资：张东麟 侯重阳 北京亚宝投资：郭常平 | | | | 高特佳：张维亮 嘉实基金：颜媛 | | 时 间 | 2018 年 6 月 27 | 日 15 点 30 分至 1 ...

证券代码：000813 证券简称：德展健康 2018 年 12 月 6 日投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|--------------------|--------|----------------------------------------------------| | | | | | | | √ | | 特定对象调研 □分析师会议 | | | □ | | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ | | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | | | □其他 （请文字说明其他活动内容） | | | | | 中信建投：贺菊颖 刘若飞 神农投资：王宇美 | | 参与单位名称及人员 | | | 信诚基金：王岩 华商基金：孙蔚 | | | | | 浙银合一：王聪 渤海资管：陈洣璠 | | 姓名 | | | 鸿道投资：王泳金 中信证券：罗啦 | | | | | 渤海汇金：纪钢 泰信基金：徐慕浩 | | 时 间 | 2018 年 12 | 月 6 | 日 16:00 点 00 分至 ...

Revenue and Profit - Revenue for Q3 2022 was ¥112,623,101.08, a decrease of 6.96% compared to the same period last year[7] - Net profit attributable to shareholders was ¥612,034.46, down 97.20% year-on-year[7] - Net profit excluding non-recurring items was ¥948,951.65, an increase of 101.14% compared to the same period last year[7] - The total operating revenue for the third quarter was CNY 416,621,519.95, a decrease of 18.7% compared to CNY 512,869,188.98 in the same period last year[25] - Net profit attributable to shareholders of the parent company was 66,124,087.08, down 46.8% from 124,478,367.92 in the previous period[30] - The total comprehensive income attributable to the parent company's owners was 66,124,087.08, down 46.8% from 124,478,367.92 in the previous period[30] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥5,702,722,433.80, a decrease of 1.30% from the end of the previous year[7] - The total assets decreased to CNY 5,702,722,433.80 from CNY 5,778,043,347.05, indicating a decline of about 1.3%[25] - Total liabilities decreased to CNY 217,072,988.13 from CNY 308,053,292.52, a reduction of approximately 29.5%[25] - Current assets increased to CNY 3,948,414,682.03, up from CNY 3,562,755,881.68, representing an increase of approximately 10.8%[25] - Non-current assets decreased significantly from CNY 2,215,287,465.37 to CNY 1,754,307,751.77, a decline of about 20.8%[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥113,120,482.14, down 10.13% year-on-year[7] - Cash flow from operating activities generated a net amount of 113,120,482.14, compared to 125,866,421.66 in the previous period, reflecting a decrease of 10.9%[34] - The company’s cash flow from investing activities showed a significant increase of 405.81% to ¥731,792,248.94 year-to-date[12] - Cash inflow from investment activities was 856,255,077.50, an increase of 33.2% from 642,790,495.59 in the previous period[34] - The net increase in cash and cash equivalents for the period was $815,392,038.50, compared to a decrease of $586,647,367.44 in the previous period[37] Shareholder Information - The total number of common shareholders at the end of the reporting period is 45,982[15] - The largest shareholder, Meilin Holdings Group, holds 19.60% of shares, totaling 437,527,456 shares[15] - The company has a significant number of pledged shares, with 3,580,000 shares pledged by Meilin Holdings Group[15] - The company has a total of 12,961,858 shares held in margin trading accounts[15] Expenses and Impairments - R&D expenses decreased by 34.73% to ¥33,896,459.56 compared to the same period last year[12] - Research and development expenses decreased to 33,896,459.56, a reduction of 34.7% from 51,929,287.83 in the previous period[28] - The company recognized an asset impairment provision of ¥12,759,700 for accounts receivable and inventory as of June 30, 2022[18] - The financial expenses showed a net income of -45,905,976.69, an increase in costs compared to -35,546,929.06 in the previous period[28] Other Significant Events - The company reported a significant decrease in government subsidies received, down 71.79% to ¥1,916,022.89 year-to-date[12] - The company experienced a 32.34% reduction in accounts receivable, totaling ¥215,699,610.89[12] - The company reported a cash balance of ¥2,303,363,501.74 as of September 30, 2022, compared to ¥1,473,720,797.44 on January 1, 2022[19] - The company repurchased 4,100,301 shares, representing 0.18% of the total share capital, at a total cost of ¥13,625,626.32[18] - The company plans to cancel 6,393,668 restricted shares from the first phase of the 2020 equity incentive plan[18] - The company has received regulatory documents from the Xinjiang Securities Regulatory Bureau regarding administrative supervision measures[18] - The company has signed a settlement agreement related to a contract dispute to protect its interests[18] - The third quarter report was not audited, indicating that the financial results are preliminary and subject to change[38]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 303,998,418.87, a decrease of 22.41% compared to CNY 391,820,103.30 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 65,512,052.62, down 36.14% from CNY 102,591,331.02 year-on-year[25]. - The net profit from non-recurring gains and losses was CNY 31,761,994.05, a decline of 65.22% compared to CNY 91,322,843.55 in the previous year[25]. - The net cash flow from operating activities was CNY 95,300,757.11, down 39.27% from CNY 156,926,755.49 in the same period last year[25]. - Basic earnings per share decreased by 36.03% to CNY 0.0293 from CNY 0.0458 in the previous year[25]. - The company reported a total revenue of 1.5 billion RMB for the first half of 2022, representing a year-over-year increase of 15%[108]. - The company expects a revenue growth of 10% for the second half of 2022, projecting total revenue to reach approximately 1.65 billion RMB[108]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,706,575,165.76, a decrease of 1.24% from CNY 5,778,043,347.05 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company increased by 1.22% to CNY 5,437,861,379.82 from CNY 5,372,112,148.36 at the end of the previous year[25]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,993,513,767.16, representing 34.93% of total assets, an increase of 9.42% compared to the previous year[65]. - Accounts receivable decreased to ¥227,437,596.04, accounting for 3.99% of total assets, a decline of 1.53% from the previous year[65]. - Inventory stood at ¥274,494,129.70, which is 4.81% of total assets, down by 0.38% year-on-year[65]. Research and Development - The company’s research and development strategy focuses on both generic and innovative drugs, primarily targeting cardiovascular diseases and metabolic disorders[36]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[108]. - Research and development expenses decreased by 34.18% to ¥22.32 million, primarily due to reduced investment in R&D projects affected by the pandemic[61]. - The company is focusing on enhancing its R&D capabilities by integrating resources from two research institutions to improve product variety and upgrade[51]. Market and Product Development - The main business of the company includes the research, production, and sales of cardiovascular drugs, with core products like Atorvastatin Calcium Tablets leading the market[34]. - The company has expanded into new business areas, including biopolypeptide products, food and beverages, and cosmetics, while also being the exclusive agent for Taiwan's Guoguang flu vaccine in mainland China[34]. - The company is actively promoting its OTC market and medical institution collaborations to enhance brand value and customer loyalty[39]. - The company is set to launch the new product, Amlodipine Atorvastatin Calcium Tablets (Nile), with 15 provinces having completed the listing application and 11 provinces pending review, expected to be officially launched in Q3 2022[50]. Risk Management and Compliance - The management has highlighted potential risks and countermeasures in the future development section of the report[5]. - The company has faced significant market and policy risks due to ongoing pharmaceutical reforms and stricter regulations[89]. - The company will implement strict internal controls to ensure drug quality in response to new regulatory standards[93]. - The company will continue to monitor industry policy changes and adapt strategies accordingly to minimize operational risks[92]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company completed the repurchase and cancellation of 6,693,668 restricted shares, accounting for 0.30% of the total share capital before cancellation[165]. - The total number of ordinary shareholders at the end of the reporting period was 47,596, with significant shareholders including Meilin Holdings at 19.65% and Shanghai Yueye at 18.55%[190]. - The company approved a share repurchase plan with a total amount not less than 178 million yuan and not exceeding 345 million yuan, pending shareholder approval[170]. Environmental Compliance - Environmental compliance reports indicate that all emissions are within regulatory standards, with no exceedances reported for the first half of 2022[108]. - The company has installed automatic monitoring equipment for water pollutants, which complies with Beijing's wastewater discharge standards, and is connected to the municipal environmental protection bureau for supervision[112]. - Jialin Pharmaceutical has established a complete set of pollution prevention facilities, including 1 RCO catalytic oxidation facility and 4 exhaust treatment facilities in the R&D workshop, all operating normally[112]. - The company has conducted a leakage emergency drill in June 2022, demonstrating its effective emergency response mechanism for environmental incidents[118].